Abramson Cancer Center at Penn Medicine
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Abramson Cancer Center at Penn Medicine sits in the top decile of US sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count).
Abramson Cancer Center at Penn Medicine: 402 sponsored US clinical trials, 74 recruiting.
Abramson Cancer Center at Penn Medicine sponsors 402 registered US clinical trials on ClinicalTrials.gov, 74 of them currently recruiting, and 235 completed. 3 of these trials are in Phase 3-4 (later-stage) and 175 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 20 trials.
Top-decile sponsor footprint
Abramson Cancer Center at Penn Medicine ranks in the top decile of sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
235 of 280 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
402 total, page 3 of 9
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
NCT04013854
Niraparib/TTFields in GBM
NCT04221503
BRCA1/2 Flu Vaccine
NCT04499534
Ostomy Rural Telehealth Training Cancer Survivors
NCT03913715
Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma
NCT03757689
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
NCT03729518
Personalized Radiation Therapy for GBM
NCT03477513
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
NCT03334500
AYA STEPS RCT: AYA Self-Management Via Texting, Education & Plans for Survivors
NCT03363711
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer
NCT03083288
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
NCT03032406
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
NCT02603341
A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
NCT02207465
Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma
NCT02153229
Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer
NCT02213497
Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer
NCT02530008
TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients
NCT01918683
The Breast Program - Translational Cancer Resource
NCT02798341
Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases
NCT02159742
Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer
NCT01352429
Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
NCT07059611
Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)
NCT06770855
Evaluating a Bidirectional Priming Intervention for Goals-of-care Communication in Oncology
NCT06955468
Nudge Strategies for DPYD Testing in Patients With Gastrointestinal Cancers Treated With Fluoropyrimidines
NCT06559462
Virtual Reality to Promote Relaxation Prior to Simulation
NCT06318338
Social Media Anti-Vaping Messages to Reduce ENDS Use Among Sexual and Gender Minority Teens
NCT06308081
Patient Ambassador
NCT06711380
Increasing Screening for Cancer Using EHR-Nudges
NCT06177795
Behavioral Economic Strategies to Improve PRO Adherence
NCT06013176
Comparison of Apixaban Versus Enoxaparin
NCT06243510
Improving Utilization of Supplemental Breast MRI Screening for Women With Extremely Dense Breasts
NCT05787249
Staying Healthy With Follow-up Care: A Mobile Chatbot Feasibility Study for AYA Cancer Survivors
NCT05863702
Lung Cancer Screening Eligibility Assessment
NCT06133816
Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients With Lung Cancer
NCT05790460
Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
NCT05721326
Using Surveys to Examine the Association of Exposure to ML Mortality Risk Predictions With Medical Oncologists' Prognostic Accuracy and Decision-making
NCT06463977
Community Support Program for Lung Cancer Screening
NCT06207435
Shared Decision-making and Colorectal Cancer Screening
NCT04748380
Project PLUS Lung Cancer Screening Promotion
NCT05937399
Predictive Analytics and Behavioral Nudges to Improve Palliative Care in Advanced Cancer
NCT05590962
Head Stabilization of Healthy Volunteers
NCT07116759
Project RESIST: Evaluating the Effects of Anti-smoking Inoculation Messages Among Young Adult Sexual Minority Women
NCT05499520
Improving Tobacco Treatment Rates for Cancer Patients Who Smoke
NCT04738643
Physical Activity in Rectal Cancer Survivors
NCT06435975
Mailed FIT Outreach 2022
NCT05341622
Behavioral Nudges to Improve Palliative Care Utilization in Advanced Cancer
NCT05365997
RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)
NCT05176756
Improving Colorectal Cancer Screening in Racially Diverse Zip Codes Using Navigation and Machine Learning (PCSNaP)
NCT05383976
Acute Effects of Cigarette Packaging and Charcoal Filtration on Perceptions, Use Behaviors, and Harm Exposure
NCT05157048
Zr89 + PET Companion Trial
NCT05279027
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 113 |
| Phase 2 | 62 |
| Phase 3 | 1 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Abramson Cancer Center at Penn Medicine pipeline
74 recruiting of 402 indexed (18% open); 235 completed (58%).
Phase mix: 3 late (III/IV) vs 175 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Abramson Cancer Center at Penn Medicine: open-pipeline peers nationwide
Peers matched on 402 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Abramson Cancer Center at Penn Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 402 trials (± recruiting share)
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
- University of Nebraska · 407 trials · 13% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
Sponsors near 18% open enrollment (± trial volume)
- University of Maryland, Baltimore · 18% recruiting · 560 trials
- Henry Ford Health System · 18% recruiting · 234 trials
- New York Institute of Technology · 18% recruiting · 49 trials
- University of California, San Diego · 18% recruiting · 775 trials
Related
What to do with this Abramson Cancer Center at Penn Medicine page
402 registered trials is a research-attention snapshot, not an endorsement of Abramson Cancer Center at Penn Medicine or any single study.
- 74 of Abramson Cancer Center at Penn Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Abramson Cancer Center at Penn Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Abramson Cancer Center at Penn Medicine pipeline card: 402 registered trials from official public datasets.Report a data error.